TARS — Tarsus Pharmaceuticals, Inc.

TARS Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Net Product Sales: $151.7 million, with a gross-to-net discount of 44%.
• Full Year 2025 Net Sales: $451.4 million, with a gross-to-net discount of approximately 45%.
• Operating Expenses: $522.3 million, primarily driven by commercial investments for XDEMVY.
• Cash Position: Approximately $418 million in cash, cash equivalents, and marketable securities.
• 2026 Guidance: Expected net product sales between $670 million and $700 million, representing over 50% growth at the midpoint.

2. Strategic Updates and Business Highlights

• XDEMVY Performance: The first FDA-approved treatment for Demodex blepharitis has helped over 0.5 million patients and is positioned for blockbuster status with sales potential exceeding $2 billion.
• Pipeline Expansion: Tarsus is advancing two clinical programs: TP-04 for Ocular Rosacea and TP-05 for Lyme disease prevention, with Phase II trials expected to initiate in 2026.
• Sales Force Investment: Plans to add 15-20 key account leaders in 2026 to deepen market penetration and enhance growth.
• Direct-to-Consumer Campaign: The campaign has achieved a positive ROI ahead of expectations, with patient awareness of XDEMVY increasing from 2% to 25%.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipated strong growth in net product sales, with a seasonal impact expected in Q1 due to deductible resets and typical industry dynamics.
• Operating Expenses: SG&A expenses projected between $545 million and $565 million, with R&D expenses expected between $115 million and $135 million.
• Long-Term Growth: Tarsus aims to build on its success with XDEMVY and expand its pipeline, targeting 1-2 new programs annually.

4. Bad News, Challenges, or Points of Concern

• Seasonal Dynamics: Q1 2026 is expected to show flat to slightly declining revenues due to typical seasonal pressures and deductible resets affecting new patient visits.
• Gross-to-Net Pressure: Anticipated increase in gross-to-net discounts in Q1, with a long-term target of 43%-45% expected to stabilize mid-year.
• Market Competition: Potential competitive pressures and the need for continued physician education and patient awareness remain critical to maintaining growth.

5. Notable Q&A Insights

• Prescribing Trends: Both ophthalmologists and optometrists are showing strong growth in prescribing XDEMVY, with 40% of core targets prescribing weekly.
• Peak Sales Timing: The $2 billion peak sales target is expected to be reached within a few years, with current penetration at less than 10% of the estimated 25 million Americans with Demodex blepharitis.
• International Market Potential: The U.S. market is prioritized for the $2 billion target, with expectations for international markets to contribute significantly, particularly in Japan.
• Clinical Trial Costs: The Phase II trial for ocular rosacea is expected to cost $7 million to $10 million, while the Lyme disease trial is projected to cost $25 million to $30 million.

Overall, Tarsus is positioned for strong growth driven by XDEMVY's market performance and strategic pipeline expansion, despite facing typical industry challenges and seasonal dynamics.